Topical, Transdermal & Ocular Drug Delivery Platform for Hard-to-Deliver Molecules

Powered by Multi-Patented Bioavailant^® Drug Delivery Technology: Optimized Bioavailability for Next-Generation Biologic Therapies

CellMedics, Inc. is a specialty biopharmaceutical company with a robust patent and intellectual property portfolio focused on the development of advanced topical, transdermal and ocular drug delivery systems and therapeutics, including a proprietary arthritis and pain relief cream. CellMedics's patented formulations are optimized to deliver therapeutic agents either directly into targeted tissues or systemically into the bloodstream--offering a safer, more effective alternative to oral or injectable administration.

At the core of this innovation is the Bioavailant^® drug delivery system--a patented, multi-mechanistic vehicle cream engineered for deep percutaneous and ocular penetration, providing significantly enhanced drug bioavailability. This platform has demonstrated the ability to deliver hard-to-absorb macromolecules, including therapeutic proteins, biologics, monoclonal antibodies, and chemotherapeutics.

Preclinical and early clinical studies have confirmed the Bioavailant^® drug delivery technology's effectiveness. Systemic bioavailability of a 50 kDa biologic was demonstrated in vivo via ELISA analysis. Local intra-articular delivery of a highly unstable 10 kDa biologic achieved 39% absolute bioavailability in joint space following topical administration.

This disruptive platform technology is particularly well-suited for molecules that are poorly absorbed, unstable in the gastrointestinal tract, or associated with hepatic toxicity. CellMedics is actively pursuing partnerships with pharmaceutical and consumer healthcare companies while also marketing its own line of branded OTC formulations. All CellMedics^® products are protected by patents.